Characteristics of patients with chronic hepatitis B in France: Predominant frequency of HBe antigen negative cases

Journal of Hepatology

Volumn 45, Issue 3, 2006, Pages 355-360

  Zarski, Jean Pierre ^a,b   Marcellin, Patrick ^c   Leroy, Vincent ^a,b   Trepo, Christian ^d   Samuel, Didier ^e   Ganne Carrie, Nathalie ^f   Barange, Karl ^g   Canva, Valérie ^h   Doffoel, Michel ⁱ   Cales, Paul ^j  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c BEAUJON HOSPITAL   (France)

^d HÔTEL DIEU   (France)

^e HÔPITAL PAUL BROUSSE   (France)

^f HÔPITAL JEAN VERDIER   (France)

^g CHU PURPAN   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ HÔPITAL CIVIL   (France)

^j ANGERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Chronic hepatitis B; Cirrhosis; Epidemiology

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; AFRICA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIA; BIRTH; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EASTERN EUROPE; FEMALE; FRANCE; FREQUENCY ANALYSIS; GENDER; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; MALE; MIDDLE EAST; PATIENT CARE; PRIORITY JOURNAL; SCORING SYSTEM; SEROPREVALENCE; SOUTHERN EUROPE; UNIVERSITY HOSPITAL; VIRUS LOAD;

ADULT; AGE FACTORS; ALANINE TRANSAMINASE; DNA, VIRAL; FEMALE; FRANCE; GENE EXPRESSION REGULATION, VIRAL; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREVALENCE; SEX FACTORS; VIRAL LOAD;

EID: 33746558210     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.03.007     Document Type: Article

References (30)

1. Ganem D., and Prince M. Hepatitis B virus infection. Natural history and clinical consequences. N Engl J Med 350 (2004) 1118-1129
2. Funk M.L., Rosenberg D.M., and Lok A.S.F. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepatol 9 (2002) 52-61
3. Brunetto M.R., Oliveri F., Coco B., Leandro G., Colombatto P., Gorin J.M., et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 36 (2002) 263-270
4. Hadziyannis S.J. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1 (1995) 7-15
5. Hadziyannis S.J., and Vassilopoulos D. Hepatitis Be antigen-negative chronic hepatitis B. Hepatology 34 (2001) 617-624
6. Lampertico P., Del Ninno E., Manzin A., Donato M.F., Rumi M.G., Lunghi G., et al. A randomized controlled trial of a 24-month course of interferon alpha2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 26 (1997) 1621-1625
7. Papatheodoridis G.V., Manesis E., and Hadziyannis J.J. The long-term outcome of interferon-treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 34 (2001) 306-313
8. Chan H.L.Y., Leung N.W.Y., Hussain M., Wong M.L., and Lok A.S.F. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 31 (2000) 763-768
9. Yoo B.C., Park J.W., Kim H.J., Lee D.H., Cha Y.J., and Park S.M. Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea. J Hepatol 38 (2003) 98-103
10. Zarski JP, Marcellin P, Cohard M, Lutz JM, Bouché C, Raïs A, a French Multicenter Group. Comparison of anti-HBe positive and HBe-antigen positive chronic hepatitis B in France. J Hepatol 1994;20:636-640.
11. Saldanha J, Gerlich W, Lelie N, Dawson P, Heerman K, Heath A, The WHO collaborative study. An international collaborative study to establish a world health organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001;80:63-71.
12. Mangia A., Chung Y.H., Hoofnagle J.H., Birken-Meyer L., Mushahwar I., and Di Bisceglie A.M. Pathogenesis of chronic liver disease in patients with chronic hepatitis B virus infection without serum HBeAg. Dig Dis Sci 41 (1996) 2447-2452
13. Tassopoulos N.C., Volpes R., Pastore G., Heathcote J., Buti M., Goldin R.D., et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine precore mutant group. Hepatology 29 (1999) 889-896
14. Chu C.J., Keeffe E.B., Han S.H., Perrillo R.P., Min A.D., Soldevila-Pico C., et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 38 (2003) 619-628
15. Knoll A., Rohihofer A., Kocharowski B., Wurm E.M., and Jily W. Prevalence of precore mutation in anti-HBe-positive hepatitis B virus carrier in Germany. J Med Virol 59 (1999) 14-18
16. Estimation des taux de prevalence des anticorps anti-VHC et des marqueurs de l'hépatite B chez les assurés sociaux du régime général de France métropolitaine, 2003-2004. Analyse descriptive, InVS, janvier 2005. http://www.invs.sante.fr/publication/2005.
17. Cadranel J.F., Lesgourgues B., Causse X., Lamek P., Bellaiche G., Bettan L., et al. Epidemiological data of hepatitis B infection in France: results of nationwide survey. Hepatology 38 (2003) 616 [Abstract]
18. Ganne-Carrié N., Williams V., Kaddouri H., Trinchet J.C., Dziri-Mendil S., Alloui C., et al. Significance of hepatitis B virus genotypes. A to E in a cohort of patients with chronic hepatitis B in the Seine Saint Denis, district of Paris (France). J Med Virol 78 (2006) 335-340
19. Poynard T., Zoulim F., Ratziu V., Degos F., Imbert-Bismut F., Deny P., et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during Lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 100 (2005) 1970-1980
20. Chu C.J., Hussain M., and Lok A.S. Quantitative serum HBV DNA levels during differents stages of chronic hepatitis B infection. Hepatology 36 (2002) 1408-1415
21. Mommega-Marin H., Mondon E., Blum M.R., and Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 37 (2003) 1309-1319
22. Fattovich G., Brollo L., Giustina G., Noventa F., Pontisso P., Alberti A., Realdi G., and Revol A. Natural history and prognostic factors of chronic hepatitis type B. Gut 32 (1991) 294-298
23. Fattovich G., Brollo L., Alberti A., Pontisso P., Giustina G., and Realdi G. Long term follow-up of anti-HBe positive chronic active hepatitis B. Hepatology 8 (1988) 1651-1654
24. McMahon B.J. The natural history of chronic hepatitis B virus infection. Semin Liver Dis 24 (2004) 17-21
25. Xu B., Hu D.C., Rosenberg D.M., Jiang Q.W., Lin X.M., Lu J.L., et al. Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China. J Gastroenterol Hepatol 18 (2003) 1345-1352
26. Wu G.C., Zhou W.P., Zhao Y.R., Guo S.H., Wang Z.Y., Zou S.B., et al. The natural history of chronic hepatitis B: a retrospective study. Hepatobiliary Pancreat Dis Int 2 (2003) 566-570
27. Marx G., Martin S.R., Chicoine J.F., and Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis 186 (2002) 295-301
28. Deuffic-Burban S., Poynard T., and Valleron A.J. Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J Viral Hepatol 9 (2002) 114-122
29. EASL International Consensus Conference On Hepatitis B. J Hepatol 2003;533-540.
30. Chronic Hepatitis B: Update of recommendations. Hepatology 2004;39:857-861.